Sunday 18 October 2026
Export NUVOQ’s income statement to Excel — free account
Holdco Nuvo Group D.G Ltd.
NUVOQ Healthcare Medical Devices
Holdco Nuvo Group D.G Ltd.’s revenue for fiscal 2023 (year ended December 2023) was $176,000.00.
0.00
0.00
NaN
Follow NUVOQ
| Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '17 | |
|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — | — |
P/S ratio |
0.00 | — | — | — | — | — |
Altman Z-Score |
(81.90) | — | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(222.78) | — | — | — | — | — |
P/Operating CF |
(13.89) | — | — | — | — | — |
P/B ratio |
0.00 | — | — | — | — | — |
Price to Tangible BV |
0.00 | — | — | — | — | — |
EV/Sales |
0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | — | — | — | — | — |
EV/Operating CF |
(13.73) | — | — | — | — | — |
EV/FCF |
(13.73) | — | — | — | — | — |
Quick Ratio |
0.02 | 0.03 | 0.30 | 9.48 | 9.48 | — |
Current Ratio |
0.05 | 0.06 | 0.54 | 14.72 | 14.72 | — |
Net Debt/EBITDA |
(0.67) | (0.39) | 0.16 | 0.03 | 4.15 | — |
Debt/Assets |
332.07% | 243.04% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.17) | (0.24) | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.05 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.44 | 0.65 | (0.27) | 0.42 | 2.74 | — |
Capex/Depreciation |
(0.17) | (0.51) | — | (1.11) | — | — |
| 63.38% | 87.36% | 0.00% | (28.67%) | 0.00% | — | |
| (930.47%) | (15.54%) | 0.00% | (13.15%) | (0.16%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
117.56% | 53.67% | (544.65%) | (2,703.85%) | (16.62%) | — |
Average Days of Receivables |
82.95 | — | — | — | — | — |
Research and Development Expense of Revenue |
4,729.55% | 0.00% | — | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
4,712.50% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,758.52% | 0.00% | — | 0.00% | — | — |
Graham Net Nets |
(0.36) | — | — | — | — | — |
Graham Number |
13.71 | — | — | — | — | — |
Earnings Yield |
(20.75%) | — | — | — | — | — |
Free Cash Flow Yield |
(7.69%) | — | — | — | — | — |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.83) | (0.79) | (0.02) | (0.85) | (0.02) | — |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | 0.00 | — |
Free Cash Flow per Share |
(0.83) | (0.81) | (0.02) | (0.86) | (0.02) | — |
Cash per Share |
0.03 | 0.07 | 0.01 | 0.05 | 0.03 | — |
Shareholders Equity per Share |
(3.74) | (2.27) | 7.22 | (0.51) | 7.16 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(3.74) | (2.27) | 7.22 | (0.51) | 7.16 | — |
Free Cash Flow |
(14.99) | (13.72) | (0.61) | (14.59) | (0.58) | — |
Working Capital |
(29.37) | (39.44) | (0.41) | 1.28 | 1.28 | — |
Capital Expenditures |
(0.04) | (0.25) | — | (0.24) | — | — |
Net Current Asset Value |
(69.40) | (39.85) | (13.30) | (269.67) | (11.61) | — |
EV/EBIT |
0.00 | — | — | — | — | — |
Capex to Sales |
0.22 | 0.00 | — | 0.00 | — | — |
Price to Operating Income |
0.00 | — | — | — | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
0.30 | 0.54 | — | 0.00 | — | — |
Cash ROIC |
27.08% | 48.18% | (0.24%) | 188.12% | (0.23%) | — |
Accounts Receivable Turnover |
0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.04 | — | — | — | — | — |
Inventory Turnover |
0.69 | — | — | — | — | — |
Average Days of Payables |
8,138.93 | 0.00 | — | — | — | — |
Days of Inventory on Hand |
38.22 | 0.00 | — | — | — | — |
Average Payables |
4.48 | — | — | — | — | — |
Average Inventory |
0.28 | — | — | — | — | — |
Average Assets |
3.62 | 133.08 | 263.93 | 262.40 | 131.20 | — |
Average Common Equity |
(53.10) | (23.67) | 121.52 | 120.39 | — | — |
Columns are period end dates